Original articleClinicalAllopurinol as Adjunctive Therapy in Intractable Epilepsy: A Double-blind and Placebo-controlled Trial
Introduction
Adenosine receptors are widely distributed throughout the body. There are increasing therapeutic applications for adenosine receptor agonists and antagonists that act through the four adenosine receptor subtypes AI, A2A, A2B, and A3 1, 2, 3, 4, 5. Adenosine has been proposed to be an endogenous anticonvulsant agent, inhibiting glutamate release from excitatory neurons and neuronal firing. Adenosine agonists therefore have potential clinical applications as antiepileptics (4). Recently, the xanthine oxidase inhibitor allopurinol, which inhibits purine degradation, was suggested for treatment of refractory epilepsy (6). It has been reported that allopurinol exerts its anticonvulsant effect through inhibiting the synthesis of quinolic acid and kynurenine, two endogenous excitatory neurotransmitters 4, 5, 6.
Nevertheless, the efficacy of allopurinol in different clinical trials is not the same 7, 8, 9, 10, 11, 12. In this double-blind randomized, placebo-controlled trial in 38 adult patients with idiopathic refractory epilepsy, we assessed the safety and antiepileptic effect of allopurinol as adjuvant agent.
Section snippets
Trial Organization
The study was a 6-month, parallel group, placebo-controlled trial undertaken in the outpatient neurology clinic of Sina General Hospital, Tehran University of Medical Sciences, Tehran, Iran from January 2003 to January 2006.
Participants
Participants were epileptic patients between the ages of 18 and 55 years. Patients who met the following criteria were admitted to the trial: clearly recognizable and reliably documented idiopathic epileptic seizure, seizure frequency not less than 3 per month, no response
Results
Thirty eight patients were randomized to trial medication. No significant differences were identified between patients randomly assigned to Group A or B with regard to basic demographic data including age and gender (Table 1). Six patients dropped out of the trial leaving 32 patients who completed the trial (two from allopurinol [one due to dizziness and one due to no response] and four patients from the placebo group [three patients due to no response and one due to nausea]). Seizure types in
Discussion
The rationale to use allopurinol for its antiepileptic effect in different types of seizures was derived from previous evidence of its efficacy in refractory seizures 7, 8, 9, 10, 11, 12. Concerning the putative mechanism of action, allopurinol is an inhibitor of the enzyme xanthine oxidase, the final step in purine metabolism, converting hypoxanthine and xanthine into uric acid 1, 2, 3, 4, 5.
Accumulation of hypoxanthine and xanthine may favor the action of the enzyme
Acknowledgments
The authors would like to thank Dr. T. Tolyat who was involved in preparing the placebo and to the staff of Iran Epilepsy Society (especially Ms. F. Javadi) for their kind help to the study team. We would also like to thank Dr. A.R. Noorian for assistance in editing the draft of the paper.
References (13)
- et al.
Role of adenosine as a modulator of synaptic activity in the central nervous system
Adv Pharmacol
(1997) - et al.
Adenosine and the nervous system. Pharmacological data and therapeutic perspectives
Gen Pharmacol
(1998) - et al.
Anticonvulsant effect of allopurinol on hippocampal-kindled seizures
Pharmacol. Biochem Behav
(1992) - et al.
Double-blind, placebo-controlled cross over trial of allopurinal as add-on therapy in childhood refractory epilepsy
Brain Dev
(1996) Physiological roles for adenosine and adenosine 5-triphosphate in the nervous system
Neuroscience
(1981)Purine receptor classification: a discussion point
Trends Pharmacol Sci
(1985)
Cited by (37)
Aberrant energy metabolism and redox balance in seizure onset zones of epileptic patients
2020, Journal of ProteomicsCitation Excerpt :Uric acid has been implicated in seizure burden in both animal models and in case studies [81,82]. Treatment with allopurinol, a hypoxanthine derivative which inhibits xanthine oxidase and prevents the formation of uric acid has been used successfully to treat seizures [81,83]. This study implicated key metabolic pathways involved in seizure generation and how their alteration may be related to the presence of refractory epilepsy (Fig. 4).
The value of serum uric acid levels to differentiate causes of transient loss of consciousness
2019, Epilepsy and BehaviorUric acid and allopurinol aggravate absence epileptic activity in Wistar Albino Glaxo Rijswijk rats
2018, Brain ResearchCitation Excerpt :Uric acid may increase the synthesis of proinflammatory molecules (Glantzounis et al., 2005; Kanellis et al., 2003), by which it can modulate activity of different types of epilepsies (Vezzani et al., 2011). Indeed, it has been established that uric acid may facilitate seizure generalization (Thyrion et al., 2016a) and reducing uric acid levels may evoke anticonvulsant/antiepileptic effects (Stover et al., 1997; Togha et al., 2007). Nevertheless, it has been demonstrated recently that chronic increase in uric acid concentration may decrease brain excitability (Thyrion et al., 2016b).
Uric acid is released in the brain during seizure activity and increases severity of seizures in a mouse model for acute limbic seizures
2016, Experimental NeurologyCitation Excerpt :In this regard, our report indicates that targeting uric acid can be of particular interest in suppressing these type of seizures. This is in line with studies in patients with intractable epilepsy that found that allopurinol is most effective against SGTCS (De Marco and Zagnoni, 1988; Tada et al., 1991; Zagnoni et al., 1994; Togha et al., 2007). In addition, allopurinol also proved to be efficient in reducing the severity of generalized seizures after hippocampal kindling in cats (Wada et al., 1992) and in blocking secondarily generalized seizures in EL mice (Murashima et al., 1998).